Drug intelligence / Profile preview

LIS1

Development stage: Phase 2
Lead developer: Xenothera
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

LIS1 is a glyco-humanized swine polyclonal antibody (GH-pAb) developed by Xenothera as an immunosuppressive agent for use in solid organ transplantation. It consists of purified IgG directed against human T lymphocytes, produced in genetically modified pigs that lack the immunogenic sugars alpha-1,3-galactose and N-glycolylneuraminic acid (Neu5Gc). By eliminating these xenoantigens, LIS1 aims to provide potent T-cell depletion while minimizing the risk of serum sickness and hypersensitivity reactions associated with traditional rabbit- or equine-derived anti-thymocyte globulins (ATGs). The drug is primarily being evaluated as an induction therapy in kidney transplant recipients to prevent acute rejection.

Other names: glyco-humanized swine anti-human T-lymphocyte polyclonal IgGGH-pAb

Beyond the preview

Go deeper on LIS1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIS1.

Explore the full profile